Johnson & Johnson vs Novartis AG
JNJ vs NVS — side-by-side comparison from reported financials. JNJ leads 4, NVS leads 7 of 11 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Novartis AG
NVS · Healthcare
$143.75+0.45%Solid
| Metric | JNJ | NVS |
|---|---|---|
| Price | $261.79 | $143.75 |
| Market cap | $631B | $273B |
| Revenue (TTM) | $97.9B | $56.7B |
| Revenue growth | +5.6% | +9.1% |
| Net margin | 21.5% | 24.7% |
| Free cash flow | $22.2B | $16.8B |
| Net cash (debt) | ($27.8B) | ($41.4B) |
| 1-year price return | +37.0% | +9.7% |
| P/E | 29.9 | 20.3 |
| P/E vs own history (cheap-side %) | 16% | 46% |
| Dividend yield | 2.00% | 3.49% |
| Return on equity | 26% | 30% |
| Altman Z-score | — | 3.50 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 140,800 | 75,267 |
Full résumé-style profiles: JNJ CV · NVS CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.